
ViaDerma Investor Information
Overview
ViaDerma, Inc. (OTC Pink: VDRM) is a pharmaceutical company committed to bringing new products to the pharmaceutical industry through innovative research and development.
ViaDerma manufactures and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company’s lead products Vitastem & Vitastem Ultra are normally applied topically using a patent-pending topical delivery system technology.
Presently, the Vitastem first aid & topical antibiotic product is used within the OTC drug market, i.e. non-prescription. ViaDerma believes the delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications.
In addition to the primary plan of developing and selling new products to the market, ViaDerma is exploring the possibility of licensing the technology to other industry leading pharmaceutical companies around the world.
Financials
Latest financial disclosures available here on OTCmarkets.com
Security Details
Authorized Shares | Outstanding Shares | Restricted | Unrestricted | Held at DTC | Float | Par Value |
---|---|---|---|---|---|---|
1,250,000,000 02/03/2023 | 1,023,620,662 02/03/2023 | 69,456,186 02/03/2023 | 954,164,476 02/03/2023 | 952,931,395 02/03/2023 | 911,600,265 07/23/2021 | 0.001 |
See VDRM security details on OTCmarkets.com
Disclosures
12/15/2022: Quarterly Report – Quarterly Report
11/15/2022: Notification of Late Filing – Notification of Late Filing
10/17/2022: Quarterly Report – Quarterly Report
05/12/2022: Quarterly Report – Quarterly Report
05/01/2022: Attorney Letter with Respect to Current Information – Attorney Letter with Respect to Current Information
03/29/2022: Annual Report – Annual Report
12/20/2021: Attorney Letter with Respect to Current Information – Attorney Letter with Respect to Current Information
11/12/2021: Quarterly Report – Quarterly Report
10/18/2021: Attorney Letter with Respect to Current Information – Attorney Letter with Respect to Current Information
08/24/2021: Annual Report – Amended and Restated
Latest financial disclosures available here on OTCmarkets.com